Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction

Urology

Volumn 49, Issue 3 SUPPL., 1997, Pages 95-101

  Su, Sai L ^a   Heston, Warren D W ^a   Perroti, Michael ^a   Cookson, Michael S ^a   Stroumbakis, Nicholas ^a   Huyrk, Robert ^a   Edwards, Elizabeth ^a   Brander, Beth ^a   Coke, Jean ^a   Soloway, Scott ^a   Lewis, Andrea ^a   Fair, William R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ANTIGEN DETECTION; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; HORMONE INHIBITION; HUMAN; MALE; METASTASIS POTENTIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 0030942107     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00175-1     Document Type: Conference Paper

References (37)

1. Ashworth TR: A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australia Medical Journal 14: 146, 1869.
2. Osborne MP, and Rosen PP: Detection and management of bone marrow micrometastases in breast cancer. Oncology 8: 25-31, 1994.
3. Neville AM: Are breast cancer axillary node micrometastases worth detecting? J Pathol 161: 283-284, 1990.
4. Hamdy FC, Lawry JB, and Anderson MA, et al: Circulating prostate-specific antigen positive cells correlate with metastatic prostate cancer. Br J Urol 69: 392-396, 1992.
5. Datta YH, Adams PT, Brobyski WR, Ethier SP, Terry VH, and Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12: 475-482, 1994.
6. Komeda T, Fukuda Y, Sando T, Kita R, Furukawa M, Nishida N, Amernormori M, and Nakao K. Sensitive detection of circulating hepatocellular carcinoma cells in peripheral blood. Cancer 75: 2214-2219, 1995.
7. Burchill SA, Bradbury MF, Pittman K, Southgate J, Smith B, and Selby P. Detection of epithelial cells in peripheral blood by reverse-transcriptase polymerase chain reaction. Br J Cancer 71: 278-281, 1995.
8. Gerhard M, Juhl H, and Kalthoff H, et al: Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 12: 725-729, 1994.
9. Mori M, Mimori K, and Inoue H, et al: Detection of cancer micrometastases in lymph nodes by reverse-transcriptase polymerase chain reaction. Cancer Res 55: 3417-3420, 1995.
10. Lee MS, Cahng KS, and Cabanillas F, et al: Detection of minimal residual cells carrying the t(14:18) by DNA sequence amplification. Science 237: 175-178, 1987.
11. Smith B, Selby P, and Southgate J, et al: Detection of melanoma cells in peripheral blood by means of reverse-transcriptase and polymerase chain reaction. Lancet 338: 1227-1229, 1991.
12. Hoon S, Wang Y, and Dale PS, et al: Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 13: 2109-2116, 1995.
13. Miyajama Y, Kato K, and Numata S, et al: Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA. Cancer 75: 2757-2761, 1995.
14. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF and Rosai J: Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 13: 1195-1200, 1995.
15. Loric S, Dumas F, Eschwege P, Blanchet P, Benoit G, Jardin A, and Lacour B: Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 41: 1698-1704, 1995.
16. Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, and DeWolf W, et al: Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 12: 2634-2639, 1994.
17. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, and Buttyan R: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43: 765-775, 1994.
18. Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole KM, McMahon D, Benson MC, and Katz AE: Molecular staging of prostate cancer, II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 153: 1373-1378, 1995.
19. Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, and Gomella LG: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992.
20. Israeli RS, Miller WH, Su SL, Powell CT, Fair WR, Samadi DS, Huyrk RF, Dabbles A, Edwards ET, Wise GO, and Heston WD: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306-6310, 1994.
21. Israeli RS, Miller WH, Su SL, Samadi DS, Powell CT, Heston WD, Wise GO, and Fair WR: Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 153: 573-577, 1995.
22. Wood DP, Banks ER, Humphrey S, McRoberts JW, and Rangnekar VM: Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 74: 2533-2540, 1994.
23. Rosen MA, Goldstone L, Lapin S, Wheeler T, and Scardino PT: Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy. J Urol 148: 331-337, 1992.
24. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy SM, and Reuter VE: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 151: 914-919, 1994.
25. Deguchi D, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, Fujihiro S, Kawamura T, Komeda H, and Horie H, et al: Detection of micro metastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 53: 5350-5354, 1993.
26. Liotta LA, Kleinerman J, and Saidel GM: Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 34: 997-1003, 1994.
27. Heston WD: Detection of hematogenous dissemination of prostate cancer by RT-PCR with primers specific for prostate-specific membrane antigen (Editorial). Clin Chem 41: 1687-1688, 1995.
28. Diamandis EP, and Yu H: Prostate cancer, prostate-specific antigen, and the polymerase chain reaction (Editorial). Clin Chem 41: 177-179, 1995.
29. Israeli RS, Powell CT, Fair WR, and Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-230, 1993.
30. Horoszewicz JS, Kawinski E, and Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostate cancer patients. Anticancer Res 7: 927-936, 1987.
31. Israeli RS, Powell CT, Corr JG, Fair WR ,and Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-1811, 1994.
32. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, and Markham AF: Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 72: 583-588, 1995.
33. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Issacs JT, and Heston WD: Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30: 105-108, 1995.
34. Su SL, Huang IP, Fair WR, Powell CT, and Heston WD: Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 55: 1441-1443, 1995.
35. Eschwege P, Dumas F, Blanchet P, Maire VL, Benoit G, Jardin A, Lacour B, and Loric S: Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 346: 1528-1530, 1995.
36. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair WR, and Reuter VE: Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 18: 979-991, 1994.
37. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood D Jr, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockage in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154: 424-428, 1995.